H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma today and set a price target of $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis’s rating is based on the promising potential of NXP900 to address the unmet needs in the post-TKI treatment landscape. The drug’s clean safety profile makes it a suitable partner for existing therapies like osimertinib and lorlatinib, which are used in treating non-small cell lung cancer (NSCLC). The Phase 1b program is structured to explore NXP900’s efficacy both as a monotherapy and in combination with other drugs, targeting specific genetic alterations such as YES1 amplification and Hippo Pathway alterations.
The initial data readouts expected in the second quarter of 2026 could serve as a significant catalyst for the stock if they meet the anticipated response rates. The fragmented post-osimertinib landscape, with limited targeted treatment options, underscores the opportunity for NXP900 to fill a critical void. This potential for NXP900 to offer a new standard of care in a landscape with few options beyond docetaxel is a key reason for the Buy rating.
In another report released on November 17, Maxim Group also maintained a Buy rating on the stock with a $17.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCT in relation to earlier this year.